Albicidin is ar ecently described natural product that strongly inhibits bacterial DNA gyrase. The pronounced activity,particularly against Gram-negative bacteria, turns it into ap romising lead structure for an antibacterial drug. Hence, structure-activity relationship studies are key for the in-depth understanding of structuralf eatures/moieties affectingg yrase inhibition, antibacteriala ctivity ando vercomingr esistance. The 27 newly synthesized albicidinsg ive profound insights into possibilities for variations of the C-terminus.F urthermore, in the present study,anovel derivative has been identified as overcoming resistance posed by the Klebsiella-protease AlbD. Structural modifications include, for example,a zahistidine replacing the previous instable cyanoalanine as the central amino acid, as well as at riazole amide bond isostere between building blocks Da nd E.
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The rise and spread of antimicrobial resistance poses one of the greatestt hreats to publich ealth. According to ar ecent study,t he number of annual deaths attributable to drug-resistant infections could reach 10 million by the year 2050. [1] The World Health Organization (WHO)a nd its member states have recognized the devastating prospecto fapost-antibiotic era and outlined the objectives to combat antimicrobialr esistance (AMR) in aG lobal ActionP lan. AP riorityP athogens List (PPL) was drawn up in ab id to promote research and development of new antibiotics, because the current clinicalpipeline is insufficient to diminish the threat posed by AMRs. [2] Since the majority of new drugs are merely modificationso fe xistingo nes, more investmenti ss orely needed to foster innovation, in particular,f or therapeutics targetingt he more challenging Gramnegative pathogens. Novel antibiotic agents are classifiedi nno-vativei ft hey fulfil at least one of the following criteria:a bsenceo fc ross-resistance to existing antibiotics, new chemical class,n ew target or new mechanism of action. [3] Exhibiting antibacteriala ctivity at nanomolar concentrations against both Gram-positive and-negative microorganisms, the oligoaromaticp eptidea ntibiotic albicidin (1) , which is producedb yt he sugarcane pathogenic bacterium Xanthomonas albilineans,r epresents ap romising lead structure in the search for an ew class of therapeutically useful anti-infectives ( Figure 1 ). [4] The phytotoxina lbicidini sap otent inhibitor of DNA gyrase, which has been similarlyf ound for the structurally relatedc ystobactamids [5] and coralmycins. [6] With ah alf maximum inhibitory concentration( IC 50 )o f4 0nm,a lbicidin exhibits an inhibitory activity similart ot hat of DNA gyrase-inhibiting quinolones and coumarins. [4, 7] Its unique structure is composed of ac innamoyl residue at the N-terminus (building block A) and ad ipeptidic moiety at the C-terminus( building blocksE and F). The latter consists of two para-aminobenzoic acids (pABAs), each decorated with adjacent methoxy and hydroxy groups.T he only stereocenter of albicidin is featuredi na nu nusual l-cyanoalanine (buildingb lock C), which has been found to be prone to hydrolysis. Lastly,t wo unsubstituted pABAs (buildingb locks Ba nd D) connect the central building block C with the two termini. [8] Figure 1. Structures of albicidin (1), azahistidine-albicidin (2)and its novel derivatives 3-28.The individual fragments of the peptide are assigned a letterf rom A to F.F or the identity of the residues investigated, see Table 1 . To maximize the bioactivityo fa lbicidin whilem inimizing the effects of knownr esistance factors structure-activity relationship (SAR) studies are imperative. The first total synthesis of albicidin [9] paved the way for initial SAR studies, which included variations of the cinnamoyl residue (buildingb lock A) [10] and the incorporation of various a-amino acidsa tt he central building block C. [11] We believe that albicidin's C-terminald ipeptidic moiety (E-F) is ak ey pharmacophoric region.A sof yet,t here has been no extensive and systematic investigation of the SAR for this important part of the molecule. Herein, we report the synthesis of 26 new albicidin derivatives with variations of the C-terminal dipeptidic group and their antimicrobiala ctivities against ab road panel of pathogens, including members of the increasingly resistant ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp.) group. All analogues were additionally tested for their capacity to inhibit DNA gyrase and for their lack of sensitivity towards two of albicidin's most important resistance factors, the binding protein AlbA [12] and the serine protease AlbD. [13] Based on our previous investigations [11] we first sought a viable replacement for the hydrolyticallyu nstable b-cyanoalanine as building block C. The noncanonical amino acid 2amino-3-(1H-1,2,3-triazol-4-yl)propanoic acid (azahistidine) appealed to us as as uitable substitute as it mimics the cyanoalanine and methoxy-asparagine moieties presenti nt he naturally occurring variants of albicidin (1) . [14] Indeed, the synthetic variant 2 exhibited superior antibacterial activity against the tested E. coli, S. typhimurium, B. subtilis and M. luteus strains,a s well as an eight-fold highera ctivity against ciprofloxacin (CIP) sensitive K. pneumoniae (Supporting Information, Ta ble S1). Consequently,w eu sed azahistidine-albicidin 2 as at emplate structuref or the subsequent SAR study:T he first set of analogues (3-17)a rises from sequential deletiono ft he methoxy and hydroxy groups present in the C-terminal dipeptidic pABA moiety ( Table 1 , green). Removing any number of substituents leads to av arying spectrumo fp otency but generally reduces overall activity.T he MIC values for trisubstitutedv ariants 3-6 suggest that the methoxy group in Ei st he most critical one regarding single deletions.I ts absence leads to as ignificant drop of activity for compound 3 against both CIP sensitivea nd resistant S. aureus, B. subtilis and M. luteus,w hile potency against the remaining panel,i ncluding all E. coli strains,i ss imilar for 3-6.I ng eneral, potency against Gram-positive pathogens gradually decreases with an increasing number of deletions of functional groups in Ea nd F, leading to al oss of activity for unsubstituted variant 17 andm onosubstituted derivatives 13-16.D espite the lack of all substituents,t he overall activity against Gram-negative pathogens only slightly decreases for 17.C ontraryt ot he remaining analogues from the deletion sequence, compound 16-bearing as ingle methoxy group in E-shows an exceptionally low potency against all tested Gram-negative pathogens.
Previous findings have shown at olerance for iso-propoxy groups as methoxy-substitutes. [14, 15] Therefore, we hoped that more hydrophobic alkoxy groups in building blocks Ea nd F might help boost activity.T ot est this hypothesis, the methoxy moietieso ft he parentc ompound 2 were successively replaced by ethoxy groups to produce synthetic analogues 18-20 (Table 1, blue). Althoughe ach of the three compoundsi nhibited DNA gyrase and showed high to very high activities throughout the series of tested pathogens-except for Klebsiella strains-the doubly substituted analogue 20 stands out ( Figure 2 ). It displays an increased spectrum of activity and the highest potency against Gram-positive B. subtilis, M. phlei and most importantlyC IP sensitive and resistant S. aureus. Remarkably,v ariant 20 is highly potent on aC IP resistant strain of Gram-negative A. baumannii,w ith MIC values below those of compound 2 by up to af actor of 65.
To expand the chemical space for the SAR study,heterocyclic derivatives 21-23,i nw hich the phenolic core structures of E and Fa re replaced by pyridines, were also synthesized ( Table 1 , purple). While introducing am ethoxypyridine as the building block Eo nly had am inor effect on the overall activity of 21,a significant dropi na ctivity-particularly against very important P. aeruginosa strains-and loss of the ability to inhibit gyrase was observed for variants 22 and 23 (Supporting Information Ta ble S1 and S2). Possibly,t he deleterious effect caused by the Table 1 . Assignment of the residuesf or albicidin analogues with sequential deletion of the substituents of the C-terminal dipeptidic moiety (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , sequential replacement of the methoxy groups with ethoxyg roups (18) (19) (20) , sequentialr eplacement of the phenolic core structure with pyridines (21-23), andw ith replacement of the carboxylic acid groupw ith a sulfonic acid group( 24). All derivatives contain azahistidine as building block C. O ne could conclude that the hydroxy group in building block Fi s imperative, but ad irect comparison of 22,f or example, with the trisubstituted ands till active analogue 6,n egates that assumption and makes adversee lectronic effects and H-bonding interactions between the nitrogen atom of the pyridine and the adjacent carboxylg roup more likely.
Since we have previously found that the amide bond between the C-terminal dipeptide (E-F) and the pABA (D) is hydrolysed by the protease AlbD [13] aseries of analogues containing amide isosteres was synthesized in an effort to escapee nzymaticc leavage. These included triazole 25,s ulfonamide 26, urea derivative 27 and the N-methyla mide 28 (Figure 1 ). [16] All but the triazole-containing analogue 25 weree ither poorly active or completely inactive in the MIC and supercoiling assays (Supporting Information, Ta bles S1 and S2). In contrast, compound 25 not only turned out to be highly potent against Gram-negative strains of E.coli DSM1 116a nd S. typhimurium TA100, with values in the range of the parent compound 2, but unlike the former it also maintained its activity in the presence of the serine protease AlbD as confirmed by agar diffusion assays (Supporting Information, Figure S4 ). The adverse results presumably stem from an alteredg eometry of the mole-cule upon introductiono fa na mide bond surrogate:T he sulfonamide is considerably larger than an amide and likely induces ap ronouncedk ink to compound 26.T he three-atom urea link is longer than the two-atom amide link and possibly leads to ad isfavouredc onformation of 27 caused by an altered intramolecular H-bondingn etwork compared to 2.T he latter reasonm ight also hold true for analogue 28,b ecause Nmethylation appearst od isrupt the H-bonding required to stabilize af avoured conformation. The same is true for the triazole-containing analogue 25,w hichi sm uch larger than the amide and lackst he ability to serve as an H-bond donor.W hat appearst ob eacontradictiona tf irst only strengthens the assumption that ac ertain degree of linearity is required for activity-thec yclic triazole moiety seems to confine af avoured geometry;h owever,t oalesser extentt han intramolecular Hbondinge nabledb yt he amide. Additional MS-cleavage experiments in the presence of AlbD were conducted for the biologically inactive compounds 26-28 to examinet he stability of the respective surrogates ( Supporting Information, Figures S8-S10 ). While the sulfonamide and urea linkersi na nalogues 26 and 27 proved to be stable towards AlbD, simple N-methylation of the amide bond did not suffice to impede enzymatic cleavage of compound 28. Due to favourable solubility characteristics offered by as ulfonic acid group, [17] we intended to identify ad erivative with a substituent in place of the C-terminal carboxylic acid that would improve the poor aqueous solubility of albicidin. However,c ompound 24 did not exhibit any antibacterial activity or gyrase inhibition (Supporting Information, Ta bles S1 and S2). The reasonf or the lack of activity might be the higher acidity of the benzenesulfonic acid (pK a % 4) or simply the larger steric demando fasulfonic acid group disfavouring interaction with the moleculart arget. [18] With regard to the synthesis, our efforts were enormous, since the synthesis strategies for the preparation of the individual building blocks had to be adapted continuously.A[2+ +4]coupling strategy turned out to be the most viable for the convergent total syntheses of novel albicidin derivatives, combining an N-terminald ipeptidic cinnamoyl residue (A-B) with a set of preassembled C-terminal tetrapeptides( C-D-E-F).
As described in the literature, [19] orthogonally protecteda zahistidine 30 was easily preparedi ntwo steps from commercially available propargylglycine 29.C ontrary to the cyano group presenti nt he natural product, the robust triazole ring is stable towardsb asic conditions, allowing for convenient cleavage of the pivaloyloxymethyl (POM) protecting group of the side chain with aq. KOH after completed assembly of the albicidin analogues.Asimple single-step conversion of 30 afforded the dipeptidic aryl alkyne 31,w hich served as as ubstrate for a subsequentc lick-reaction to form the triazole linker presenti n tetrapeptide 49 (Scheme 1A,G). The synthesis of the tetrasubstituted pABA building block 36 from regioselectively protected dihydroxybenzoic acid 34 was achieved in am ultigram scale following an alternative route compared to the original synthetic strategy.T he key intermediate 35 served as au niversal precursor for O-alkylation, which enabled simple introduction of ethyl groups (Scheme 1C). By omitting the hydroxy group in building block F, an acid-labile sulfonate protecting group strategy could be adopted for the preparation of dipeptide 40,l eading to the corresponding albicidin analogue 24 via tetrapeptide 47 (Scheme1D,G). [20] Synthesis of N-methyl amide 28 required selectivem onomethylation of aniline 41 in the presence of methyl iodide. This wasa chieved by installing at rifluoroacetylp rotecting group prior to methylation to generate compound 42.T he protecting group could easily be removed afterwardsw ith K 2 CO 3 in MeOH to afford the desired dipeptide 43 (Scheme 1E). In the final step of the assembly,a ll tetrapeptides were coupled to the active ester 33,w hich had been prepared in two steps from previously reported cinnamoyl buildingb lock 32 (Scheme 1B). Activation of the A-B dipeptide with pentachlorophenol( PCP), rather than previously used HATU, led to higher yields and considerably facilitated the final purification step by reversed-phase preparative HPLC.
In summary,w eh ave carriedo ut the first systematic SAR study for albicidin'sC -terminal dipeptidic pABA moiety.I nitially, our extensive endeavouru nearthed an ew lead structure, azahistidinea lbicidin 2,e xhibiting both superior antibacterial activity and chemical stability to the natural product 1.T he doubly ethoxy-substituted compound 20 exhibitso utstanding potencya nd ab roadened spectrumo fa ctivity,i ncluding aC IP-resistant strain of A. baumannii. The triazole moiety in compound 25 was identified as av iable structural motif to overcome cleavage by the Klebsiella-protease AlbD while preserving biological activity.P rospectively,o ur resultsw ill help improve as tructure-activity guided drug design approacho nt he path to developa nu rgently needed new clinicalcandidate.
